Abstract
Apatinib is a new oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2. It has been proven effective in treating multiple solid tumors. Herein, we report the case of a 67-year-old Chinese patient who was diagnosed with recurrent and malignant transformation of intrahepatic biliary cystadenoma. After multidisciplinary team discussion, the team considered that the remaining liver volume was insufficient for surgical resection. The patient refused chemotherapy and radiotherapy and was willing to take apatinib. Initially, the patient experienced severe tongue ulcers and difficulty eating. The dose of apatinib was then adjusted to 250 mg/day. To date, he has been taking apatinib for 48 months. Regular re-examination showed that the tumor had significantly decreased in size. On January 16, 2021, a CT scan revealed a tumor diameter of 4.5 cm. In our case, the patient achieved partial response and progression-free survival(PFS) of 48.0 months. During treatment, the patient’s appetite and mental state were expected. The treatment did not induce hypertension, fatigue, hand-foot syndrome, or liver and kidney damage. Apatinib may be an option for the treatment of advanced intrahepatic biliary cystadenocarcinoma. Its toxicity is controllable and tolerable. The exact curative effect still needs to be evaluated in more cases.
Background
Apatinib (Hengrui Pharmaceutical Co., Ltd., Shanghai, China.) is a multi-target, small-molecule tyrosine kinase inhibitor that can selectively inhibit the tyrosine kinase activity of vascular endothelial growth factor receptor-2 (VEGFR-2) and inhibit tumor neovascularization, thus suppressing tumor growth. Clinical observations have shown that apatinib has a specific anti-tumor effect in various tumors (–). However, there are no reports on the effectiveness and safety of apatinib in treating patients with intrahepatic biliary cystadenocarcinoma (IBCA). Here, we report, for the first time, the case of a 67-year-old male patient with IBCA who showed a satisfactory response to low-dose apatinib in our department.
Case presentation
On December 10, 2016, a 67-year-old man was admitted to our hospital to further evaluate a liver mass discovered during routine postoperative examination in a local hospital. The patient had no clinical discomfort. Past History: On December 2, 2011, the patient underwent a left lateral hepatectomy because of abdominal magnetic resonance imaging (MRI) showing a multilocular cystic mass in the left lateral lobe of the liver (Figures 1A–C). Postoperative pathology confirmed intrahepatic biliary cystadenoma (IBC) (Figure 1D). No recurrence was found during regular follow-up 3 years after the operation. On December 15, 2016, a computed tomography (CT) scan of the abdomen in our hospital revealed a 16×12 cm mass with cystic and solid masses, accompanied by mixed density and papillary excrescences. After the contrast agent’s infusion, the lesions showed inhomogeneous enhancement, with a low-density necrotic area in the arterial phase and decreased enhancement in the venous phase (Figures 2A–C). Serum CA19-9 level was 8.4 U/mL(normal range: 0-27 U/mL), Serum CEA level was 1.67 ng/mL (normal range: 0-5 ng/mL). After multidisciplinary team discussion, we diagnosed the patient with recurrent and malignant transformation of IBC. We assessed that the patient’s remaining liver volume was not sufficient to undergo liver resection. The patient resisted radiotherapy, chemotherapy, and interventional therapy and only agreed to take apatinib treatment. After signing an informed consent form, the patient started taking apatinib 500 mg/day on February 3, 2017. After taking medicine for 10 days, the patient experienced severe tongue ulcers and difficulty in eating. Therefore, the patient stopped taking apatinib and was treated symptomatically. After 15 days, the discomfort symptoms were relieved, and the dose of apatinib was adjusted to 250 mg/day. MRI (on May 25, 2017) showed that the tumor had shrunk to 12×9 cm, which indicated that the patient achieved stable disease (Figures 2D–F). On July 15, 2020, the patient underwent tension-free repair of the right inguinal hernia in our department and recovered well after the operation. On January 16, 2021, a CT scan showed that the tumor had a diameter of 4.5 cm. No noticeable enhancement was observed (Figures 3A–D). During the follow-up period, no other organs or lymph node metastasis were observed found. The serum tumor marker levels of CEA, CA199, were within the normal range. To date, this patient has been taking apatinib for 48 months. The patient achieved a partial response (PR) according to the Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 standard, and PFS of 48.0 months was achieved. No adverse events, such as hypertension, hand-foot syndrome, liver and kidney function damage, thyroid dysfunction, and digestive tract discomfort, were detected during treatment. The low-dose apatinib was well-tolerated by the patient. The patient agreed to continue taking the medication and refused radical surgical resection.
Figure 1
Figure 2
Figure 3
Discussion
Intrahepatic bile duct cystic tumor (IBCT) is a rare hepatic cystic tumor, and its aetiology remains unknown. It accounts for 5% of all intrahepatic cystic diseases (). Due to progress in understanding IBCT, there is an increasing number of related reports. Its actual incidence should be higher, as it is often misdiagnosed as a simple hepatic cyst or other cystic lesions (). Most of the lesions are single, mostly in the intrahepatic bile duct and rarely in the extrahepatic bile duct; lesions in the gallbladder are rare (), and most cysts are different IBCT. IBCT is classified into two histological types: IBC and IBCA (, ). IBC is a precancerous lesion with a malignant transformation rate of up to 30% ().
IBCA is a multilocular liver malignant tumor originating from the IBC and is composed of mucous-secreting epithelial cells (, ). Previous studies have reported that this disease often occurs in middle-aged women (). Recent studies have found that the disease is more common in men aged between 55 and 60 years, and the incidence is higher in Asian people (). Devaney et al. () proposed two subtypes of IBCA: (1) malignant transformation caused by IBC with or without ovarian stroma, which is the most common subtype in women, and (2) malignant transformation caused by intrahepatic bile duct or bile duct malformation, which is the subtype that is more common in men.
The clinical manifestations of IBCA and IBC are very similar, making diagnosis difficult. If an ultrasound shows that the intracapsular sound transmission is poor, the cyst fluid is thick, the intracapsular septum is thickened, and the mural nodule is larger than 1.0 cm with coarse calcification; cystadenocarcinoma may also be indicated (). Choi et al. suggested that CT scan and MRI were excellent in facilitating the differential diagnosis of the two diseases (). Calcification in the cyst wall, solid masses in the cyst (wall nodules), and thickening of the cyst wall or septum have a tendency to be diagnosed as cystadenocarcinoma. Enhanced CT scans can identify, with greater clarity, the intracapsular septum and potential solid masses in the cyst; however, MRI can determine, with greater clarity, whether the intracapsular septum is connected to the bile duct, thus improving diagnosis rate and assisting in making the operation plan (). For imaging diagnosis, with respect to suspected IBC or IBCA, there is a risk of transmission, in addition to the limited diagnostic value of the fluid composition characteristics of the needle tract. Therefore, invasive examination or percutaneous fine-needle aspiration cytology is not recommended ().
Surgical resection is the first choice for treating IBCT because of the difficulty in diagnosing IBCA before surgery and the high malignant transformation rate (). The possibility of IBC or IBCA should be considered for patients with atypical hepatic cystic lesions. For any suspected hepatobiliary cystadenoma, standard lobectomy should be performed as far as possible to ensure complete resection of the cystic wall and to reduce the recurrence rate (). During an operation of a patient with IBCA, destroying the integrity of the tumor should be avoided, the scope of resection should be at least approximately 2 cm from the edge of the cyst, and the cyst fluid should be prevented from leaking into the abdominal cavity, which will cause extensive metastasis while ensuring an excellent margin to achieve good prognosis (). Atypical IBC can easily be misdiagnosed as a hepatic cyst. When thickening of the cyst wall occurs, yellow vegetation on the cyst wall, turbid flocculent or viscous fluid accompanied by bile-like fluid or dark red bloody fluid, or different shapes of polycystic liver cyst fluid may be observed during an operation; in such cases, multi-point sampling is recommended to avoid the omission of bad lesions and the possibility of secondary operation (). In this case, the patient should undergo resection after drug treatment. Unfortunately, the patient refused to receive surgery or pathological puncture for accurate pathological result.
IBCA is not sensitive to radiotherapy or chemotherapy, and advanced patients lack effective treatment. Radiotherapy and chemotherapy are suitable for patients with advanced tumors, unresectable operations, or late remission of symptoms (, ). In a study by Zhao et al. (), patients with advanced IBCA were treated with docetaxel combined with cisplatin and hyperthermia, and after six cycles of treatment, the lesions did not progress. There have been no reports of targeted therapy for IBCA.
Tumour angiogenesis is a critical step in tumor growth and metastasis. It plays a vital role in providing oxygen, nutrition, and growth factors for tumors; therefore, anti-angiogenesis agents can treat solid tumors (). Apatinib is a small-molecule tyrosine kinase inhibitor that highly selectively binds to and strongly inhibits VEGFR-2, decreasing VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular formation (). The China Food and Drug Administration recommended apatinib as a third-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma in 2015. Besides, apatinib shows excellent potential in various solid tumors, such as non-small cell lung cancer (), breast cancer (), hepatocellular carcinoma (), pancreatic cancer (), and ovarian cancer (). Adverse reactions to apatinib include hypertension, hand-foot syndrome, albuminuria, fatigue, anorexia, and elevated transaminase level; most of these adverse events are of grade1-2, which can be relieved by drug withdrawal or reduction (, ). We report a patient with advanced IBCA who showed a very encouraging response to apatinib. The patient achieved a PR, and a PFS of 48.0 months was achieved, which shows that angiogenesis also plays a vital role in cholangiocarcinoma’s occurrence and development. In addition, apatinib was well-tolerated by the patient, which further proved its safety and suitability. It is suitable as the choice of long-term maintenance treatment. We also think that adverse effects were controlled by dose reduction, or interruption, and symptomatic treatment. Through this patient’s treatment process, combined with relevant literature reports at home and abroad, we get the following enlightenment: We administer drug dose according to the patient’s body weight and age. In the beginning, a medium dose is recommended, which can be increased if the patient is well tolerated; On the contrary, if the adverse reaction is severe, the dose can be reduced to maintain the long-term curative effect.
Conclusions
IBCA is a rare malignant tumor of the liver. IBCA is not sensitive to radiotherapy and chemotherapy, and patients with advanced IBCA lack effective treatment. We think that apatinib may be a new option for the Treatment of IBCA. Its efficacy and safety need to be confirmed by further study..
Funding
This study was supported by the National Science Foundation of Guangdong Province (Grant no: 2018A030307076).
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.
Ethics statement
The studies involving human participants were reviewed and approved by The Ethics Committee of Affiliated Hospital of Guangdong Medical University. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
YY and ML performed the surgery. WC and WM wrote the original draft. CY collected and arranged imaging and pathological data. LL designed the study and revised the manuscript. All authors contributed to the article and approved the submitted version.
Acknowledgments
We appreciate the imaging department’s support, pathology during the patient’s diagnosis, treatment, and draft process. We would like to thank Editage (www.editage.cn) for English language editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.676092/full#supplementary-material
References
1
LiJQinSXuJGuoWXiongJBaiYet al. Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial. J Clin Oncol (2013) 31(26):3219–25. doi: 10.1200/JCO.2013.48.8585
2
ZhaoLYangYGaoQ. Efficacy and Safety of Nivolumab Plus Apatinib in Advanced Liver Carcinosarcoma: A Case Report. Immunotherapy (2019) 11(8):651–6. doi: 10.2217/imt-2018-0214
3
ZhangYFanWWangYHuangGLiJ. Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. Cancer Control (2019) 26(1):1073274819872216. doi: 10.1177/1073274819872216
4
TsiftsisDChristodoulakisMde BreeESanidasE. Primary Intrahepatic Biliary Cystadenomatous Tumors. J Surg Oncol (1997) 64(4):341–6. doi: 10.1002/(sici)1096-9098(199704)64:4<341::aid-jso17>3.0.co;2-5
5
ErdoganDBuschORRauwsEAvan DeldenOMGoumaDJvan-GulikTM. Obstructive Jaundice Due to Hepatobiliary Cystadenoma or Cystadenocarcinoma. World J Gastroenterol (2006) 12(35):5735–8. doi: 10.3748/wjg.v12.i35.5735
6
KimHHHurYHKohYSChoCKKimJW. Intrahepatic Biliary Cystadenoma: Is There Really an Almost Exclusively Female Predominance? World J Gastroenterol (2011) 17(25):3073–4. doi: 10.3748/wjg.v17.i25.3073
7
DevaneyKGoodmanZDIshakKG. Hepatobiliary Cystadenoma and Cystadenocarcinoma. A Light Microscopic and Immunohistochemical Study of 70 Patients. Am J Surg Pathol (1994) 18(11):1078–91. doi: 10.1097/00000478-199411000-00002
8
SangXSunYMaoYYangZLuXYangHet al. Hepatobiliary Cystadenomas and Cystadenocarcinomas: A Report of 33 Cases. Liver Int (2011) 31(9):1337–44. doi: 10.1111/j.1478-3231.2011.02560.x
9
SoochanDKeoughVWanlessIMolinariM. Intra and Extra-Hepatic Cystadenoma of the Biliary Duct. Review of Literature and Radiological and Pathological Characteristics of a Very Rare Case. BMJ Case Rep (2012) 2012:bcr0120125497. doi: 10.1136/bcr.01.2012.5497
10
IshakKGWillisGWCumminsSDBullockAA. Biliary Cystadenoma and Cystadenocarcinoma: Report of 14 Cases and Review of the Literature. Cancer (1977) 39(1):322–38. doi: 10.1002/1097-0142(197701)39:1<322::aid-cncr2820390149>3.0.co;2-p
11
XuHXLuMDLiuLNZhangYFGuoLHLiuCet al. Imaging Features of Intrahepatic Biliary Cystadenoma and Cystadenocarcinoma on B-Mode and Contrast-Enhanced Ultrasound. Ultraschall Med (2012) 33(7):E241–9. doi: 10.1055/s-0031-1299276
12
ChoiHKLeeJKLeeKHLeeKTRheeJCKimKHet al. Differential Diagnosis for Intrahepatic Biliary Cystadenoma and Hepatic Simple Cyst: Significance of Cystic Fluid Analysis and Radiologic Findings. J Clin Gastroenterol (2010) 44(4):289–93. doi: 10.1097/MCG.0b013e3181b5c789
13
WangKKongFDongMZhouJLiY. Diagnosis and Treatment of Intrahepatic Biliary Cystadenoma: Experience With 14 Cases in a Single Center. Med Oncol (2014) 31(11):274. doi: 10.1007/s12032-014-0274-3
14
DelisSGTouloumisZBakoyiannisATassopoulosNParaskevaKAthanassiouKet al. Intrahepatic Biliary Cystadenoma: A Need for Radical Resection. Eur J Gastroenterol Hepatol (2008) 20(1):10–4. doi: 10.1097/MEG.0b013e3282f16a76
15
MartelGAlsharifJAubinJMMargineanCMimeaultRFairfull-SmithRJet al. The Management of Hepatobiliary Cystadenomas: Lessons Learned. HPB (Oxford) (2013) 15(8):617–22. doi: 10.1111/hpb.12026
16
ZhouJPDongMZhangYKongFMGuoKJTianYL. Giant Mucinous Biliary Cystadenoma: A Case Report. Hepatobiliary Pancreat Dis Int (2007) 6(1):101–3.
17
Al-QahtaniHamadH. Diagnostic Uncertainty of Hepatobiliary Cystadenoma: Report of 11 Cases and Review of the Literature. J Taibah Univ Med Sci (2016) 11(1):19–25. doi: 10.1016/j.jtumed.2015.11.001
18
HanazakiKYoshizawaKMoriH. Hepatic Arterial Infusion Chemotherapy of Cisplatin for Biliary Cystadenocarcinoma. Hepatogastroenterology (1999) 46(25):462–4. doi: 10.1016/S0016-5107(99)70472-4
19
IyamaSTakahashiYShintaniNFujikawaKOhkuboSSatoYet al. A Case of Recurrent Biliary Cystadenocarcinoma Successfully Treated With 5FU/CDDP Systemic Chemotherapy. Nihon Shokakibyo Gakkai Zasshi (2006) 103(10):1163–8.
20
ZhaoYWangJ. Intrahepatic Biliary Cystadenocarcinoma: One Case Report and Literature Review. Chin J Gastroenterol Hepatol (2019) 28(02):238–40.
21
DingJChenXDaiXZhongD. Simultaneous Determination of Apatinib and Its Four Major Metabolites in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Study. J Chromatogr B Analyt Technol BioMed Life Sci (2012) 895-896:108–15. doi: 10.1016/j.jchromb.2012.03.027
22
LiJQinSXuJXiongJWuCBaiYet al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol (2016) 34(13):1448–54. doi: 10.1200/JCO.2015.63.5995
23
WuFZhangSXiongAGaoGLiWCaiWet al. A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-Squamous Non-Small-Cell Lung Cancer. Clin Lung Cancer (2018) 19(6):e831–42. doi: 10.1016/j.cllc.2018.06.002
24
HuXCaoJHuWWuCPanYCaiLet al. Multicenter Phase II Study of Apatinib in Non-Triple-Negative Metastatic Breast Cancer. BMC Cancer (2014) 14:820. doi: 10.1186/1471-2407-14-820
25
LiCMLiuZCBaoYTSunXDWangLL. Extraordinary Response of Metastatic Pancreatic Cancer to Apatinib After Failed Chemotherapy: A Case Report and Literature Review. World J Gastroenterol (2017) 23(41):7478–88. doi: 10.3748/wjg.v23.i41.7478
26
ZhangDHuangJSunYGuoQ. Long-Term Progression-Free Survival of Apatinib Monotherapy for Relapsed Ovarian Cancer: A Case Report and Literature Review. Onco Targets Ther (2019) 12:3635–44. doi: 10.2147/OTT.S198946
27
YuWCZhangKZChenSGLiuWF. Efficacy and Safety of Apatinib in Patients With Intermediate/Advanced Hepatocellular Carcinoma: A Prospective Observation Study. Medicine (Baltimore) (2018) 97(3):e9704. doi: 10.1097/MD.0000000000009704
Summary
Keywords
apatinib, intrahepatic biliary cystadenoma, intrahepatic biliary cystadenocarcinoma, targeted therapy, intrahepatic bile duct cystic tumor
Citation
Yang Y, Mai W, Chen W, Yang C, Li M and Liu L (2021) Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation. Front. Oncol. 11:676092. doi: 10.3389/fonc.2021.676092
Received
04 March 2021
Accepted
15 June 2021
Published
28 June 2021
Volume
11 - 2021
Edited by
Wen Zhou, Central South University, China
Reviewed by
Shanshan Li, University of California, San Francisco, United States; Luo Jia, Central South University, China
Updates
Copyright
© 2021 Yang, Mai, Chen, Yang, Li and Liu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mingyi Li, limingyi63@163.com; Lijuan Liu, 64740052@qq.com
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.